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Sentinel lymph node (SLN) biopsies have widely been used for the detection of occult LN metastasis of 
malignant melanoma (MM).  In addition to conventional biomarkers,  we assessed the diagnostic and 
prognostic signiﬁcance of melanoma-initiating cell (MIC) markers in SLNs of MM.  We examined the 
expressions of gp100,  MART-1 and tyrosinase mRNA for routine diagnosis and those of ABCB5,  
CD133,  nestin,  KDM5B,  NGFR and RANK mRNA as MIC markers.  The presence of micrometastasis 
was conﬁrmed immunohistochemically using antibodies to S-100,  HMB-45,  MART-1,  and tyrosinase.  
Discordance between immunohistochemical and molecular data was observed in 14 of 70 (20.0ｵ) 
patients,  among whom ﬁve (7.1ｵ) were positive for only molecular markers; two of these ﬁve patients 
tested positive for micrometastasis by repeated immunohistochemical stainings.  The quantitative 
expression levels of gp100,  MART-1,  and tyrosinase mRNA were signiﬁcantly higher in the metastatic 
LNs; the cut-oﬀ values remain to be elucidated.  ABCB5 mRNA expression was detected more fre-
quently in the metastatic SLNs (p＜0.05) and in the group of patients with recurrence.  To make a deﬁ-
nite diagnosis of metastasis,  we still need a combination of immunohistochemical and molecular 
probes.  ABCB5 might be a suitable molecular marker for the detection of melanoma-initiating cells in 
SLNs.
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he authors of a large-scale clinical study con-
cluded that the sentinel lymph node (SLN) 
biopsy-based management of malignant melanoma (MM) 
prolonged the disease-free survival and melanoma-
speciﬁc survival of a group of patients with nodal 
metastases of intermediate-thickness melanomas,  deﬁned 
as 1.20 to 3.50mm [1].  Standard SLN biopsies were 
performed using 3 steps: (1) lymphoscintigraphy,  fol-
lowed by (2) intraoperative injection of vital dye 
around the primary tumor,  and (3) conﬁrmation of the 
radioactivity of the LNs by gamma probe [2].  
Although the accurate detection of metastasis in SLNs 
is essential for the management of MM patients,  both 
false-positive and false-negative results may occur 
even though sensitive immunohistochemical methods 
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using speciﬁc antibodies to MART-1/Melan-A,  HMB-
45,  S-100 protein and Tyrosinase are used [3].  
Although quantitative RT-PCR methods using a 
primer set speciﬁc for gp100,  MART-1,  and tyrosi-
nase facilitate the detection of occult metastases in 
SLNs,  it is still unknown whether such micrometas-
tases detected only by PCR have prognostic signiﬁ-
cance [4].
　 Recent studies have demonstrated the presence of 
cancer-initiating cells (CICs) with stem cell-like char-
acteristics [5-8].  In melanoma,  similar CIC popula-
tions designated as melanoma-initiating cells (MICs) 
have been identiﬁed.  These MICs have been reported 
to express speciﬁc cell surface markers including 
ABCB5,  CD133,  nestin,  KDM5B (JARID1B),  NGFR 
(CD271) and RANK [9-14].  In addition to the con-
ventional cellular and molecular markers used for 
evaluating SLN biopsies,  we have examined the 
expression of some MIC-related markers in SLNs,  
and assessed the possibility of using these MIC mark-
ers as prognostic indicators,  as MICs are thought to 
play a critical role in melanoma progression [9,  12].
Materials and Methods
　 Patients. The study was approved by the Ethical 
Committee of the Okayama University School of 
Medicine (no. 968) and carried out according to the 
guidelines set by the Institutional Review Board.
　 The study included a total of 70 patients who 
underwent an SLN biopsy for primary cutaneous 
melanoma between 1997 and 2010 at Okayama 
University Hospital (Okayama,  Japan).  The clinical 
and pathologic characteristics of the 70 patients are 
listed in Table 1.  There were 33 men and 37 women,  
and the median age was 60.6 years.  More than one-
half of the primary melanomas were located on an 
extremity,  followed by the trunk and the head and 
neck.  The median and mean tumor thicknesses were 
2.70mm and 2.41mm,  respectively (range 0-13mm).  
Ulceration of the primary tumor was present in 45.7ｵ 
of  the cases.
　Tissues. A total of 141 SLNs were identiﬁed 
and excised from 70 melanoma patients.  Fresh frozen 
tissues of 14 primary melanoma tumors,  seven normal 
skin samples,  and 18 non-melanoma lymph nodes were 
used for molecular analyses.
　 Pathological and immunohistochemical stud-
ies for SLNs. A total of 141 SLNs from 70 mela-
noma patients were subjected to histological and 
molecular genetic analyses.  To detect SLN metasta-
sis,  we used a central slice of each SLN for the his-
tological diagnosis.  Each SLN was stained with 
hematoxylin-eosin (HE).  To conﬁrm micrometastases,  
we stained all of the sections with antibodies to S100 
(DAKO,  Glostrup,  Denmark),  MART-1 (clone 
M2-7C10,  COVANCE,  Dedham,  MA,  USA),  tyro-
sinase (clone T311,  Leica Biosystems,  Nussloch,  
Germany) and HMB-45 (clone HMB45,  DAKO) anti-
bodies.  The secondary antibody was Histoﬁne® Simple 
Stain MAX PO (MULTI) (Nichirei Biosciences,  
Tokyo,  Japan).
　 Conventional RT-PCR analysis. The periph-
eral portions of the SLNs were snap-frozen and used 
for molecular genetic analyses.  Eighteen histologi-
cally proven normal lymph nodes (nLNs) from patients 
with non-melanoma disease were used as a control.  
We extracted total RNA from the LN samples using 
the RNeasy Mini Kit (Qiagen,  Hilden,  Germany),  and 
the total RNA was reverse-transcribed using the 
SuperScript First Strand Synthesis System 
(Invitrogen,  Carlsbad,  CA,  USA).  The primers used 
for the detection of target genes (gp100,  MART-1,  
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Table 1　 Patient clinicopathological data
Mean age (years) 60.6
n %
Sex Male 33 47.1
Female 37 52.9
Primary Site Head and neck 13 18.6
Trunk 16 22.9
Extremities 41 58.6
Breslow thickness ≦1.00 10 14.3
1.01-2.00 13 18.6
2.01-4.00 26 37.1
＞4.00 20 28.6
Unknown 1 1.4
Mean 2.41
Median 2.7
Range 0-13
Ulceration Present 32 45.7
Absent 38 54.3
Unknown 0 0.0
total N 70
tyrosinase,  GAPDH) were as follows: gp100,
5ʼ-GCTTGGTGTCTCAAGGCAACT-3ʼ and 
5ʼ-CTCCAGGTAAGTATGAGTGAC-3ʼ; MART-1,  
5ʼ-CACGGCCACTCTTACACCAC-3ʼ and 
5 -ʼGGAGCATTGGGAACCACAGG-3ʼ; and tyrosinase,  
5ʼ-TTGGCAGATTGTCTGTAGCC-3ʼ and 
5ʼ-AGGCATTGTGCATGCTGCTT-3ʼ.
　 PCR was performed in the following manner: one 
cycle of denaturation at 94℃ for 2min as the ﬁrst 
step,  followed by 35 successive cycles of PCR com-
prising 94℃ for 1min,  53℃ for 1min,  and 72℃ for 
1min.  The PCR products were analyzed by electro-
phoresis using a 1ｵ agarose gel.  After electrophore-
sis,  the gels were photographed using ultraviolet 
transillumination.
　 Quantitative reverse transcription (qRT)-
PCR analysis. TaqMan Gene Expression Assays 
(Applied Biosystems ABI,  Foster City,  CA,  USA) 
were used to analyze the expression levels of human 
GP100 (assay ID: Hs00202752_m1),  human MART-1 
(assay ID: Hs00192503_m1),  and human tyrosinase 
(assay ID: Hs00166289_m1) in 90 SLNs from 48 
patients.  In 83 SLNs from 43 patients,  we also 
performed quantitative RT-PCR analyses for 
putative MIC markers,  including human ABCB5 
(assay ID: Hs00846307_s1),  human CD133 
(assay ID: Hs00202752_m1),  human nestin 
(assay ID: Hs00192503_m1),  human JARID1B 
(assay ID: Hs00846307_s1),  human NGFR (CD271) 
(assay ID: Hs00166289_m1) and human RANK 
(assay ID: Hs00166289_m1) following the manufac-
turerʼs instructions (User bulletin #2 by Applied 
Biosystems).
　 GAPDH mRNA was detected by the probe VIC-
CATCCATGACAACTTTGGTAMGB and using the 
primers 50-CTTAGCACCCCTGGCCAAG-30 and 
50-TGGTCAT GAGTCCTTCCACG-3,  and it was 
used as an internal control to validate the RNA for 
each sample.  We also performed quantitative reverse 
transcription (qRT)-PCR analyses for MIC markers 
in 14 primary melanoma tissues,  seven normal skin 
samples,  and 18 non-melanoma lymph nodes.  Each 
mRNA expression was calculated as the expression 
relative to GAPDH mRNA.  Each assay was per-
formed in duplicate,  and the mean threshold cycle (Ct) 
was used for the analysis.
Results
　 Eﬀectiveness of a combination study with 
immunohistochemical and molecular markers.
The removed SNLs were ﬁrst screened by both an 
immunohistochemical study using antibodies to S-100,  
HMB-45,  MART-1 and tyrosinase (Fig.  1) and RT-PCR 
ampliﬁcation using primer sets speciﬁc for gp100,  
MART-1 and tyrosinase cDNA (Fig.  2).  The SLNs 
were deﬁned as metastasis-positive when a group of 
atypical cells was positive for one or more of the 
immunohistochemical markers,  even if the samples 
were negative for the molecular markers.  If a positive 
result was obtained by molecular markers alone,  but 
a negative result was obtained for immunohistochemi-
cal markers,  the samples were re-examined using 
immunohistochemistry (IHC).
　 Discordance between the immunohistochemical and 
molecular data indicating metastasis was observed in 
14 of the 70 (20ｵ) patients,  among whom ﬁve (7.1ｵ) 
patients were positive for only molecular markers and 
nine patients (12.9ｵ) were positive for only immuno-
histochemical markers (Table 2).  Two of the ﬁve (40ｵ) 
patients who were positive only by RT-PCR were 
revealed to have micrometastases by repeated immu-
nohistochemical staining.  In the remaining three 
patients metastases could still not be detected after 
re-evaluation by immunohistochemistry.  We have 
observed no recurrence in the three patients who were 
positive only by RT-PCR while recurrence and death 
occurred in nine patients who were positive only by 
immunohistochemical markers.
　 Quantitative analysis of MM-associated mol-
ecules in the SLNs. The quantitative expressions 
of gp100,  MART-1,  and tyrosinase mRNA were sig-
niﬁcantly higher in the metastatic SLNs than in the 
non-metastatic SLNs (Fig.  3).
　 The metastatic SLNs were conﬁrmed by HE and 
IHC stains.  However,  it was diﬃcult to set the cut-oﬀ 
values because of the wide range of values.  In the 15 
tumor-positive sentinel lymph nodes that were con-
ﬁrmed by HE and IHC,  we evaluated the expression 
levels of gp100,  MART-1,  and tyrosinase mRNA by 
determining the distance of tumor cell invasion from 
the capsules,  based on the following deﬁnitions: S1,  
ｦ0.3mm; S2,  ＞0.3 ｦ1.0; and S3,  ＞1.0mm [15].  
The expression levels tended to increase according to 
the S classiﬁcation,  but the diﬀerence was not sig-
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G3PDH gp100 MART-1 Tyrosinase
1500bp
1000bp
500bp
1, 5, 9, 13; sentinel lymph node
2, 6, 10, 14; primary lesion of melanoma
3, 7, 11, 15; negative control
4, 8, 12, 16; positive control
Fig. 2　 RT-PCR assays in SLNs of malignant melanoma.  The peripheral portions of the sentinel lymph nodes (SLNs) were snap-frozen 
and used for molecular genetic analyses.  RT-PCR ampliﬁcation using primer sets speciﬁc for gp100,  MART-1 and tyrosinase cDNA.  
GAPDH was used as a housekeeping gene.
S-100 HMB-45
MART-1 Tyrosinase
Fig. 1　 Immunohistochemical stains of SLNs of malignant melanoma.  To conﬁrm micrometastases,  we stained all of the sections with 
antibodies to S100,  MART-1,  HMB-45 and tyrosinase antibodies.
niﬁcant (Fig.  4).
　 The expression of MIC markers in the SLNs.
Among the six MIC markers including ABCB5,  
CD133,  nestin,  KDM5B,  NGFR and RANK mRNA,  
the ABCB5 mRNA was speciﬁcally detected in the 
primary lesions of MM that metastasized to the SLNs,  
but not in the cases without metastasis or normal skin 
(Fig.  5),  although a signiﬁcant diﬀerence was not 
observed.  The expression of ABCB5 mRNA in pri-
mary lesions was detected in four of the eight (50ｵ) 
patients with metastasis to SLNs,  and in three of the 
six (50ｵ) patients without metastasis.  One of the 
former four patients had recurrence in the mediasti-
num LNs and died,  while the latter three patients had 
no recurrence.  The KDM5B mRNA expression levels 
were signiﬁcantly lower in the primary lesions com-
pared to the normal skin samples (p＜0.05).
　 In the SLNs,  the expression levels of ABCB5 
mRNA were higher in the metastasis-positive LNs 
compared to the metastasis-negative and normal LNs 
(p＜0.05).  Up-regulation was not observed in the 
expression levels of CD133,  nestin,  KDM5B,  NGFR 
or RANK mRNA in any group (Fig.  6).  These results 
indicated that ABCB5 might be a candidate marker for 
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＋; a tumor positive SLN conﬁrmed by HE and Immunohisitochemical (IHC) stains (n＝24)
－; a tumor negative SLN conﬁrmed by HE and IHC stains (n＝66)
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Fig. 3　 The quantitative expression of gp100,  MART-1,  and tyrosinase mRNA in SLNs.  The quantitative expressions of gp100,  MART-1,  
and tyrosinase mRNA were signiﬁcantly higher in the metastatic SLNs than in the non-metastatic SLNs.
Table 2　 Histological and molecular analysis in SLNs of mela-
noma
Histological
analysis
(HE/IHC)
Molecular
analysis
(RT-PCR)
Results
Patients (%) Lymph nodes
－ － 　38/70 (54.3%) 94/141
－ ＋
　　5/70 (7.1%)
＊→3/70 (4.3%)
11/141
9/141
＋ － 　 9/70 (12.9%) 11/141
＋ ＋
　18/70 (25.7%)
＊→20/70 (28.6%)
25/141
27/141
total 70/70　 141/141
＋(histological analysis); tumor cells conﬁrmed by HE and or at 
least one marker stained by immunohistochemical study.
＋(molecular analysis); at least one marker expression of mRNA 
conﬁrmed by RT-PCR.
＊Two of the ﬁve patients who were positive only by RT-PCR were 
revealed to have micrometastases by repeated immunohistochemi-
cal staining.
the detection of MICs in SLNs as well as primary 
lesions,  and for the prediction of recurrence.
　 Prediction of the recurrence of MM by con-
ventional molecular markers and ABCB5. Of 
the 41 patients who underwent SLN biopsy,  nine 
experienced recurrence.  ABCB5 mRNA was detected 
in seven of the 32 (21.9ｵ) patients without recur-
rence,  and in four of the nine (44.4ｵ) patients with 
recurrence.  The expression of ABCB5 mRNA might 
be found more frequently in MM patients with recur-
rence.
　 In contrast,  eight of the nine patients (88.9ｵ) in 
the recurrence group expressed all three of the 
molecular markers,  MART-1,  tyrosinase,  and gp100 
mRNA,  while the non-recurrence group showed a low 
three-way positivity,  in only seven of the 32 (21.9ｵ).  
Thus,  the detection of all of three molecular markers 
MART-1,  tyrosinase,  and gp100 mRNA may predict 
the recurrence more accurately than the expression of 
ABCB5 mRNA alone.
　 A total of 15 patients were positive for all three 
conventional RT-PCR markers,  and eight of them 
experienced relapse.  Four of the eight patients with 
relapse were also positive for ABCB5,  while six of 
the seven patients without relapse were negative for 
ABCB5 (p＝0.14,  by chi square test).  Thus,  
ABCB5 expression in SNLs may help to further 
stratify the group of patients who are positive for all 
three conventional markers,  MART-1,  tyrosinase,  
and gp100 (Table 3).
Discussion
　 In addition to conventional immunohistochemical 
markers,  we assessed the usefulness of the molecular 
markers gp100,  MART-1 and tyrosinase mRNA.  Five 
of 70 patients (7.1ｵ) were negative in the immunohis-
tochemical study but positive for one or more of the 
22 Acta Med.  Okayama　Vol.  69,  No.  1Suzuki et al.
S-classiﬁcatin was deiﬁned by the distance of tumor cell invasion from the capsules. S1; 0.3mm or less (n＝3), 
S2; more than 0.3 until 1.0mm or less (n＝5), and S3; more than 1.0mm (n＝7).
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Fig. 4　 The quantitative expression of gp100,  MART-1,  and tyrosinase mRNA in S-classiﬁcations of tumor-positive SLNs.  In the 15 
tumor-positive sentinel lymph nodes that were conﬁrmed by HE and IHC,  we evaluated the expression levels of gp100,  MART-1,  and 
tyrosinase mRNA by determining the distance of tumor cell invasion from the capsules.  The expression levels tended to increase according 
to the S classiﬁcation,  but the diﬀerences were not signiﬁcant.
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Fig. 5　 The expression of MIC markers in primary lesions of MM and normal skin.  Primary lesions with SLN metastasis conﬁrmed by HE 
and IHC (n＝8).  Primary lesions without SLN metastasis conﬁrmed by HE and IHC (n＝6).  Normal skin samples (n＝7).  Among the six 
MIC markers including ABCB5,  CD133,  Nestin,  CD271,  JARID1B and RANK mRNA,  the ABCB5 mRNA was speciﬁcally detected in the 
primary lesions of MM that metastasized to the SLNs,  but not in the cases without metastasis or normal skin.  The KDM5B mRNA expres-
sion levels were signiﬁcantly lower in the primary lesions compared to the normal skin samples (p＜0.05).
molecular markers.  In our conﬁrmation study,  the 
further sectioned specimens turned out to be positive 
in two of these ﬁve patients by immunohistochemical 
examination.  The false-negative results were thus 
corrected by the detection of molecular markers.
　 In contrast,  nine of the 70 patients (12.9ｵ) who 
were positive in the immunohistochemical examination 
showed a negative result in the molecular analysis.  
Since the RT-PCR assay is thought to be far more 
sensitive than the immunohistochemical method used 
here,  it might be critical that the tissue specimens are 
sectioned from the proper portion of the SLNs con-
taining metastatic cells.
　 It is widely agreed that an H&E-based histopatho-
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Fig. 6　 The expression of MIC markers in melanoma SLNs and normal LNs.  SLN＋,  a tumor-positive SLN conﬁrmed by HE and IHC 
stains (n＝23).  SLN－,  a tumor-negative SLN conﬁrmed by HE and IHC stains (n＝60).  Normal LN,  lymph nodes from patients with 
non-melanoma disease (n＝18).  In the SLNs,  the expression levels of ABCB5 mRNA were higher in the metastasis-positive LNs than in 
the metastasis-negative and normal LNs (p＜0.05).  No clear diﬀerences were observed in the expression levels of CD133,  nestin,  
KDM5B and NGFR mRNA in each group.
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Table 3　 Clinical and molecular features of 41 patients of malignant melanoma
Pt No. Age Sex TT Ulcer Stage HE/IHC S-class
RT-PCR qRT-PCR 
Chemotherapy Recurrence Death OS (months)
MART-1 TYR GP100 ABCB5
1 74 M 3.25 ＋ ⅡB － － － － － IFNβ ? ?
2 46 F 6.5 ＋ ⅢA ＋ 2 ＋ ＋ ＋ － D-IFNβ 2 course ＋(lung meta.) ＋ 62
3 63 F 0.75 － ⅢA ＋ 3 ＋ ＋ ＋ ＋ D-IFNβ 6 course ＋(mediastinal meta.) ＋ 82
4 64 M 5.2 ＋ ⅢC ＋ 3 ＋ ＋ ＋ ＋ IFNβ ＋(liver meta.) ＋ 69
5 69 M 8.4 ＋ ⅢA ＋ 1 ＋ ＋ ＋ － D-IFNβ 6 course ＋(liver meta.) ＋ 44
6 71 M 2.05 ＋ ⅡA － ＋? － ＋? － ND － 96
7 49 F 4.2 － ⅢA ＋ 2 ＋ ＋ ＋ － D-IFNβ 6 course － 95
8 78 M 3.9 ＋ ⅢC ＋ 2 ＋ － － ＋ D-IFNβ 6 course － 92
9 66 M 2.2 － ⅡA － － － － － D-IFNβ 3 course － 87
10 84 F 5.9 ＋ ⅡC － － － － － ND － 84
11 68 M 3.3 － ⅢA ＋ 3 ＋ ＋ ＋ － D-IFNβ 6 course － 82
12 73 F ＞4.0 － ⅡB － － － － ＋ D-IFNβ 3 course － 79
13 69 M 3.5 － ⅢB ＋ 3 － － － － ND ? ?
14 57 M 1.7 ＋ ⅡA － － － － － D-IFNβ 3 course － 74
15 58 F 1.5 ＋ ⅡA － ＋ ＋ ＋ － D-IFNβ 3 course － 70
16 27 F 2.1 ＋ ⅡB － － － － － D-IFNβ 3 course － 70
17 43 F 0.8 － ⅠA － － － － － ND － 69
18 75 F 2.9 ＋ ⅡB － － － － － D-IFNβ 3 course － 68
19 78 M 7.2 ＋ ⅢB ＋ 3 ＋ ＋ ＋ ＋ D-IFNβ 6 course ＋(lung meta.) ＋ 37
20 78 M 7.2 ＋ ⅢB ＋ 1 ＋ ＋ ＋ － D-IFNβ 2 course ＋(mediastinal LN meta.) ＋ 27
21 64 M 1.3 ＋ ⅢB ＋ 3 － － ＋? ＋ D-IFNβ 5 course － 65
22 84 F 1.6 － ⅢA ＋ 2 ＋ ＋ ＋? ＋ ND － 64
23 76 F in situ － 0 － － － ＋? ＋ ND － 62
24 32 M 13 ＋ ⅡC － － － － － D-IFNβ 4 course － 60
25 78 M 1.8 ＋ ⅡA － － － － － D-IFNβ 2 course － 58
26 91 F 5.6 ＋ ⅢC ＋ 3 ＋ ＋ ＋ ＋ ND ＊＋ 46
27 74 F 2.8 ＋ ⅡB － ＋ ＋ ＋ － IFNβ － 57
28 51 F 1.2 ＋ ⅡA － － － － － D-IFNβ 2 course － 54
29 66 F 10 ＋ ⅢB ＋ 3 － － ＋ － D-IFNβ 4 course ＋(lung, liver, brain meta.) ＋ 8
30 75 M 7.2 － ⅢB － － － － － IFNβ － 51
31 75 F 0.9 － ⅢA ＋ － － － ＋ D-IFNβ 5 course － 51
32 21 F 5 ＋ ⅡC － － － － － D-IFNβ 5 course － 50
33 22 M 0.9 － ⅠA － － － － － ND － 49
34 22 M 2.7 － ⅡB － － － － － D-IFNβ 3 course － 49
35 81 F in situ － 0 － － － － － ND － 48
36 57 F 3.2 － ⅡA － － － － － D-IFNβ 3 course － 47
37 71 F 4.2 ＋ ⅢB ＋ 3 － － － － D-IFNβ 5 course － 43
38 61 M 1.1 － ⅢA ＋ 2 ＋ ＋ ＋ － D-IFNβ 5 course － 45
39 87 F 13 ＋ ⅢC ＋ 3 ＋ ＋ ＋ ＋ IFNβ ＋(in-transit meta.) ＋ 11
40 71 M 3.8 ＋ ⅢB ＋ 2 ＋ ＋ ＋ － D-IFNβ 6 course ＋(in-transit meta.) ＋ 39
41 69 F ＞4.0 ＋ ⅢB ＋ 2 ＋ ＋ ＋ － IFNβ － 31
TT,  tumor thicness; HE,  Hematoxylin and Eosin Staining; IHC,  Immonohistochemistry Staing; TYR,  tyrosinase; OS,  overall survival; IFNβ,  interferonβ local injection; D-IFNβ,  DTIC intravenous injection
＋interferonβ local injection; ND,  not done; ＊,  death of other diseases.
logical analysis alone results in an unacceptably high 
rate of false-negative results.  It was shown that in 
patients who developed metastases in a regional lymph 
node basin that was originally diagnosed as negative by 
a histopathological SLN evaluation,  re-evaluation by 
immunohistochemistry revealed SLN micrometastases 
in 80ｵ of the cases [16].  In a retrospective analysis 
of the 143 patients with initially histopathologically 
negative sentinel lymph node biopsies,  10 of the 15 
cases (67ｵ) with nodal progression were found to be 
false-negative due to a previous erroneous routine 
reading of H&E specimens [17].  However,  in another 
study a rate of only 12ｵ false-negative results was 
reported [18].  The accurate detection of microme-
tastases therefore requires the combination of histo-
pathological analysis and a molecular analysis.
　 Our quantitative RT-PCR assay for the molecular 
markers demonstrated that the expression levels of 
gp100,  MART-1,  and tyrosinase mRNA were signiﬁ-
cantly higher in the metastatic LNs compared to the 
non-metastatic LNs (p＜0.05) and were related to the 
distance of invasion from the LN capsule.  A quantita-
tive assay is thus useful for comparative studies of 
metastatic and non-metastatic groups,  but it is diﬃcult 
to show the evidence of metastasis in individual cases.
　 Of the CIC markers examined in the present study,  
the expression of ABCB5 mRNA was more speciﬁc for 
the primary melanoma tissue than the other CIC 
markers,  although the positivity rates were rather 
low.
　 In the metastatic LNs,  ABCB5 mRNA expression 
was detected signiﬁcantly more frequently than in the 
non-metastatic SLNs (p＜0.05).  A follow-up study 
revealed that the ABCB5 mRNA-positive cases had a 
higher frequency of recurrence compared to that of the 
negative group (44.4ｵ vs. 21.9ｵ).  ABCB5 is a novel 
human ABC transporter encoded on chromosome 
7p15.3.  Previous studies have shown that ABCB5,  
like ABCB1,  acts as an energy-dependent drug eﬄux 
transporter for the ﬂuorescent probe rhodamine-123.  
Moreover,  ABCB5 marks CD133＋ progenitor cells 
among human epidermal melanocytes (HEMs),  and the 
transporter is expressed by a subset of G3361 malig-
nant melanoma cells.
　 In physiological progenitor cells,  ABCB5 functions 
to maintain membrane hyperpolarization,  thereby 
serving as a negative regulator of cell fusion of the 
expressing progenitor subset and,  as a consequence,  
of culture growth and diﬀerentiation.  Remarkably,  
membrane hyperpolarization is associated with the 
MDR phenotype of certain cancer cells,  and although 
the potential role of ABCB1 as a determinant of 
membrane potential was examined recently,  this 
transporter was not found to be responsible in the 
investigated cancer types [19].  It has been reported 
that the melanoma chemoresistance mediator ABCB5 
could represent a molecular marker deﬁning tumori-
genic malignant-melanoma-initiating cells (MMICs),  
because its expression also characterizes progenitor 
cell subsets in physiological skin [9].
　 In conclusion,  although ABCB5 is a possible 
molecular marker for the detection of melanoma-initi-
ating cells in SLNs,  its diagnostic value for the pre-
diction of recurrence should be studied carefully.  At 
the present time,  in order to make the deﬁnite diagno-
sis of metastasis,  a combination of results from 
immunohistochemical and molecular probes is still 
required.
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